nifenazone has been researched along with Cardiomyopathies, Primary in 1 studies
nifenazone: RN given refers to parent cpd; structure
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Li, Y | 1 |
| Hu, Q | 1 |
| Xi, Y | 1 |
| Xing, Z | 1 |
| Zhang, Z | 1 |
| Huang, L | 1 |
| Wu, J | 1 |
| Liang, K | 1 |
| Nguyen, TK | 1 |
| Egranov, SD | 1 |
| Sun, C | 1 |
| Zhao, Z | 1 |
| Hawke, DH | 1 |
| Li, J | 1 |
| Sun, D | 1 |
| Kim, JJ | 1 |
| Zhang, P | 1 |
| Cheng, J | 1 |
| Farida, A | 1 |
| Hung, MC | 1 |
| Han, L | 1 |
| Darabi, R | 1 |
| Lin, C | 1 |
| Yang, L | 1 |
1 other study available for nifenazone and Cardiomyopathies, Primary
| Article | Year |
|---|---|
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin.
Topics: Animals; Antipyrine; Cardiomyopathies; Cell Line; Disease Models, Animal; Dystrophin; Enzyme Inhibit | 2020 |